Clinical Trials: Central vs Local Labs

Benefits of Central Lab Standardization: Lessons Learned from Global Audits

Posted on digi By digi

Central laboratories have become an essential part of global clinical trial infrastructure. Their appeal lies in their ability to provide standardized testing, centralized data processing, and streamlined communication between sponsors, CROs, and investigators. Central lab standardization can mitigate variability across sites, support protocol adherence, and improve regulatory compliance. However, centralization also brings its own set of challenges—especially when regulatory audits assess consistency, data traceability, and SOP alignment.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Turnaround Time Comparison: Local vs Central – Best Practices for FDA & EMA

Posted on digi By digi

Turnaround time (TAT) for laboratory test results plays a significant role in maintaining trial timelines, ensuring subject safety, and meeting regulatory expectations. Whether dealing with pharmacokinetic endpoints, safety labs, or biomarker readouts, delays in lab data can compromise protocol compliance and data integrity. FDA and EMA inspections frequently highlight TAT discrepancies as audit findings, especially in trials involving multiple sites with varied lab models.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Test Menu Limitations in Local Labs – Best Practices for FDA & EMA

Posted on digi By digi

Local laboratories play an important role in expediting clinical trial operations, especially in decentralized or rural research settings. However, they often lack the comprehensive test menus, harmonized methodologies, and qualification processes offered by central labs. This leads to inconsistent data, challenges in comparing results across sites, and significant inspection findings.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Compliance Playbook – Sample Shipment Logistics to Central Labs

Posted on digi By digi

Central laboratories offer standardized testing, improved data integrity, and harmonized methods in global clinical trials. However, the logistics of safely and compliantly shipping biological samples from collection sites to these labs remains a complex, risk-prone task. Improper handling, temperature excursions, or delayed shipments can lead to sample degradation and data loss.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Case Study Series – Managing Delays in Lab Result Reporting and CAPA Solutions

Posted on digi By digi

Delays in laboratory result reporting can severely impact the integrity of clinical trial data, delay dosing decisions, and trigger protocol deviations. Regulatory agencies such as the FDA and EMA require that lab data—especially safety-related values—be promptly and accurately reported for patient protection and trial oversight.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Harmonization of Lab Ranges Across Regions with Risk-Based Oversight Strategies

Posted on digi By digi

In multinational clinical trials, inconsistencies in laboratory reference ranges across countries and regions can lead to protocol deviations, data interpretation issues, and regulatory scrutiny. Variations may arise due to differences in population demographics, lab equipment, assay methodology, or even local guidelines. Harmonizing these ranges is essential for generating valid and comparable clinical data.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Compliance Playbook – Protocol-Driven Lab Selection

Posted on digi By digi

In clinical trials, the selection of a central or local laboratory is rarely arbitrary. It must be driven by the clinical protocol’s scientific, logistical, and regulatory requirements. A mismatch between lab capability and protocol expectations can result in protocol deviations, delayed data availability, noncompliance, and failed inspections.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management

Building SOPs for Lab Result Interpretation and Query Resolution

Posted on digi By digi

Laboratory results form the foundation of many safety and efficacy endpoints in clinical trials. Inadequate interpretation of lab values or delayed response to data queries can jeopardize subject safety, trial timelines, and data integrity. Regulatory bodies such as the FDA and EMA have consistently emphasized the need for well-defined procedures around lab data handling—particularly when multiple labs (central and local) are involved.

Click to read the full article.

Central vs Local Labs, Laboratory and Sample Management